MTP hit with new suspension order as Medway problems linger
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has issued new administrative actions against Mitsubishi Tanabe Pharma (MTP) and its Bipha manufacturing subsidiary, marking the latest in a years-long string of regulatory transgressions at MTP.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.